NewTimeSpace News: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) announced that the NMPA has accepted a supplemental New Drug Application (sNDA) for its core product, the TROP2-targeted ADC sacituzumab tirumotecan (sac-TMT, JIATAILEI®), for a new indication: the first-line treatment of recurrent or metastatic triple-negative breast cancer (TNBC) in patients with PD-L1 CPS < 10 or those who have previously received PD-1/PD-L1 inhibitors at an early stage. The application has been included in the priority review and approval procedure, marking the sixth accepted indication application for sac-TMT.
NewTimeSpace News: On 30 July 2026, XPENG-W (09868.HK) drifted downwards amid volatile afternoon trading. As of 14:48, the stock traded at HK$50.40, down 2.61%. The company’s cumulative vehicle exports have surpassed 100,000 units. Tang Zhikun, General Manager of XPeng’s International Business, stated at a global launch event held in Munich, Germany recently that the firm has rolled out a detailed globalisation strategy targeting annual overseas sales of one million vehicles by 2030.
NewTimeSpace (newtimespace.com) reported that on July 30, 2026, the chip theme continued to weaken, while ASMPT (00522.HK) bucked the trend and rose. As of 13:23, the stock was quoted at HKD 138.400, up 1.10%.
NewTimeSpace (newtimespace.com) reported that on July 30, 2026, the robotics theme weakened significantly, with Xiaomi-W (01810.HK) opening higher then falling lower. As of 13:10, the stock was quoted at HKD 31.100, down 2.45%.
NewTimeSpace News: MicroPort NeuroScienti c Corporation announced on 30 July that the Artemis Dream® Self-expanding Intracranial Sirolimus-eluting Stent System developed by its subsidiary has passed the application for special review of innovative medical devices issued by the National Medical Products Administration (NMPA) and entered the special review procedure (fast track).
NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals announced on 29 July that its subsidiary Fujian Shengdi has received the Clinical Trial Approval Notice for HRS5580 for Injection issued by the NMPA, authorising the launch of Phase II clinical trials for the prevention of postoperative nausea and vomiting.
NewTimeSpace News: Hengrui Pharmaceuticals announced in an announcement dated 29 July that Insulin Sudelidec Injection, a self-developed Category 1 therapeutic biological product of the Company, has obtained marketing approval from the National Medical Products Administration (NMPA) for the treatment of type 2 diabetes in adults.
On July 29, 2026, Hong Kong's three major indices surged significantly. The Hang Seng Index rose 1.96%, the Hang Seng Tech Index gained 2.84%, and the Hang Seng China Enterprises Index advanced 2.22%. Total turnover on the Hang Seng Index reached HKD 312.2 billion, up markedly from the previous trading day. Southbound capital recorded a net outflow of HKD 5.589 billion.The autonomous driving sector strengthened across the board. The Ministry of Industry and Information Technology accelerated the drafting of the "15th Five-Year Plan" for intelligent connected vehicles. Xiaomi-W (01810.HK) rose nearly 9%, CiDi (03881.HK) gained nearly 6%, and Hesai-W (02525.HK) climbed over 6%.
NewTimeSpace News: On 29 July 2026, BIDU-SW (09888.HK) strengthened in afternoon trading. As of 14:38, its intraday price stood at HK$103.00, up 1.38%. On 28 July, Baidu Apollo Go partnered with Free Now, a subsidiary of Lyft Group, to launch public road tests in London.
NewTimeSpace (newtimespace.com) reported that on July 29, 2026, the chip theme continued to weaken, with SMIC (00981.HK) falling sharply. As of 13:22, the stock was quoted at HKD 65.200, down 5.64%.
NewTimeSpace (newtimespace.com) reported that on July 29, 2026, the robotics theme strengthened with volatility, and UBTECH (09880.HK) edged up. As of 13:15, the stock was quoted at HKD 81.650, up 1.94%.
NewTimeSpace News: Insilico Medicine announced on July 29 that ISM6331, an AI-powered pan-TEAD inhibitor independently developed by the company, has received Fast Track Designation from the U.S. FDA.
On July 28, 2026, Hong Kong's three major indices rallied in volatile trading. The Hang Seng Index closed up 0.41%, the Hang Seng Tech Index rose 0.61%, and the Hang Seng China Enterprises Index gained 0.85%. Turnover reached HKD 250.6 billion, up from the previous trading day. Southbound capital recorded a net outflow of HKD 2.495 billion.The large-model sector suffered a heavy blow, with Zhipu (02513.HK) closing down over 18% and MINIMAX-W (00100.HK) falling more than 14%. HSBC Research lowered its target price for Zhipu, and the open-sourcing of Kimi K3 intensified competition in the large-model arena, triggering a concentrated flight of capital from the sector.
NewTimeSpace News: On 28 July 2026, RoboSense (02498.HK) traded weaker in the afternoon. As of 14:45, the intraday price stood at HK$21.60, down 3.57%. For the cumulative period January–April 2026, the penetration rate of passenger vehicles factory-fitted with standard L2 intelligent driving functions reached 34.7%, a year-on-year drop of 6.7 percentage points. Meanwhile, the penetration rate of passenger vehicles equipped with standard L2 and above driving functions hit 35.7%, representing a year-on-year increase of 17.1 percentage points.
NewTimeSpace (newtimespace.com) reported that on July 28, 2026, the chip theme weakened, with HUA HONG GRACE (01347.HK) falling sharply. As of 13:28, the stock was quoted at HKD 136.200, down 8.34%.
NewTimeSpace News: Keymed Biosciences Inc. (02162.HK) announced on 28 July that CMG901, a CLDN18.2-targeted ADC, achieved primary endpoint in its global Phase III trial and significantly improved overall survival for patients receiving second-line and later-line gastric cancer treatment. It is the first CLDN18.2 ADC demonstrating OS benefit in gastric cancer. AstraZeneca estimates the product’s peak sales to range from USD3 billion to USD5 billion. The Company reminds investors of commercialisation uncertainties.
